Skip to main content
Yantai Zhenghai Bio-Tech Co., Ltd. logo

Yantai Zhenghai Bio-Tech Co., Ltd. — Investor Relations & Filings

Ticker · 300653 ISIN · CNE100002NZ1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 968 across all filing types
Latest filing 2026-03-30 Remuneration Information
Country CN China
Listing Shenzhen Stock Exchange 300653

About Yantai Zhenghai Bio-Tech Co., Ltd.

https://www.zhbio.com

Yantai Zhenghai Bio-Tech Co., Ltd. specializes in the research, development, production, and sale of regenerative medicine materials. The company focuses on tissue engineering and biomaterials to provide solutions for clinical repair and functional reconstruction. Its core product portfolio includes the Heal-All oral repair membrane, absorbable hard cerebral (spinal) membrane patches, and skin repair membranes. These products are widely utilized in stomatology, neurosurgery, and orthopedics. The company leverages advanced processing technologies to ensure biocompatibility and safety in its medical devices. By integrating research with clinical needs, it develops innovative bone repair materials and other biological scaffolds designed to facilitate natural tissue regeneration.

Recent filings

Filing Released Lang Actions
关于2026年度董事、高级管理人员薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the 2026 annual remuneration scheme for the company's directors and senior management. It details the salary structure, including fixed and performance-based components, for directors and senior executives. The document is a formal disclosure of compensation plans rather than a full remuneration report or proxy statement. It does not contain detailed compensation tables or executive pay disclosures typical of a DEF 14A filing, but rather announces the remuneration scheme. Therefore, it fits best under the category of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors.
2026-03-30 Chinese
关于举办2025年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the holding of the 2025 annual online earnings presentation (业绩说明会) by the company. It references that the full 2025 annual report has already been published on the official disclosure website. The document invites investors to participate in the online earnings explanation meeting and submit questions. The content is primarily about the scheduling and details of the earnings presentation event, not the report itself. The document length is short (799 characters), and it serves as a notice for the event rather than containing financial data or the report itself. Therefore, it fits the category of Investor Presentation (IP) rather than Annual Report (10-K) or Earnings Release (ER).
2026-03-30 Chinese
对外投资管理制度
Governance Information Classification · 95% confidence The document is titled '对外投资管理制度' which translates to 'External Investment Management System' and is issued by the company's board of directors. It outlines internal policies and procedures for managing the company's external investments, including decision-making authority, approval processes, supervision, and control measures. The document is a governance or internal control policy document rather than a financial report, earnings release, or announcement. It does not contain financial statements, audit results, or regulatory filings. It is a detailed governance-related document describing internal rules and management practices related to investments. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 3945 characters, which is substantive and not a brief announcement or certification, supporting this classification.
2026-03-30 Chinese
募集资金管理制度
Capital/Financing Update Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and is issued by 烟台正海生物科技股份有限公司. The content extensively discusses the management, use, supervision, and regulatory compliance related to the company's raised funds (募集资金). It references laws and regulations related to capital raising, the establishment of special accounts for raised funds, usage restrictions, approval procedures, and auditing requirements. The document is a detailed internal policy or system document governing the management of raised capital rather than a financial report, earnings release, or announcement. It does not contain financial statements or results but rather governance and procedural rules about capital management. This fits best under the category of Capital/Financing Update (CAP), as it relates to the management and regulatory compliance of capital raised by the company. The document length (7967 characters) and detailed procedural content support this classification rather than a short announcement or a report publication announcement. Therefore, the classification is CAP with high confidence.
2026-03-30 Chinese
2025年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 90% confidence The document is a summary table of non-operating fund occupation and other related party fund transactions for the year 2025, prepared by a company. It contains detailed financial data about related party transactions, including amounts and accounting subjects. The document is short (957 characters) and appears to be a specific financial disclosure related to related party transactions rather than a full financial report or announcement. It does not match categories like Annual Report, Interim Report, or Earnings Release. It is also not a regulatory announcement or certification. Given the nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous financial disclosures that do not fit other specific categories.
2026-03-30 Chinese
董事会对独立董事独立性评估的专项意见
Governance Information Classification · 95% confidence The document is a special opinion from the board regarding the independence assessment of independent directors, referencing regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange guidelines. It does not contain financial statements, audit results, or detailed management reports. It is a governance-related disclosure about board members' independence, fitting the category of Governance Information (CGR). The document length is short and focused on governance compliance rather than financial or audit reporting.
2026-03-30 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.